A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Brexanolone (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Proof of concept
- Sponsors Sage Therapeutics
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 03 Mar 2016 According to Sage Therapeutics media release, data presented at the. 68th American Academy of Neurology (AAN).
- 22 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.